NeurologyLive® Friday 5 — July 19, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Efficacy of Fenfluramine in Reducing Generalized Tonic-Clonic Seizures: Kelly Knupp, MD

The pediatric epileptologist at Children's Hospital Colorado talked about a comprehensive review of various studies assessing fenfluramine in severe seizures associated with developmental and epileptic encephalopathies. [WATCH TIME: 5 minutes]

2: Considerations to Better Diagnose Nonhemorrhagic Cerebral Amyloid Angiopathy: Andreas Charidimou, MD, PhD

The neurologist and assistant professor at Boston University Medical Center provided forward thoughts on improving the diagnosis of milder, asymptomatic cases of cerebral amyloid angiopathy. [WATCH TIME: 4 minutes]

3: Understanding the Significant Role of Secondary Symptoms of Parkinson Disease

Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.

4: NeuroVoices: Marie Eugene, DO, on Career Development for Clerkship Directors

The neurologist and clerkship director at the University of Connecticut provided perspective on the developing role of clerkship directors and the value they provide to neurology departments.

5: Role of Alpha-Synuclein in Accurate and Early Diagnosis of Parkinson Disease: Sameea Husain-Wilson, DO

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]